Technology
Health
Biotechnology

Zai Lab

$29.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.82 (-2.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Zai Lab and other stocks, options, ETFs, and crypto commission-free!

About

Zai Lab Limited American Depositary Shares, also called Zai Lab, is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. Read More The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Employees
88
Headquarters
Shanghai, Shanghai
Founded
2014
Market Cap
1.47B
Price-Earnings Ratio
Dividend Yield
Average Volume
148.61K
High Today
$29.78
Low Today
$29.03
Open Price
$29.70
Volume
28.90K
52 Week High
$31.97
52 Week Low
$14.29

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Medical
Pharmaceutical
2017 IPO

News

Simply Wall StMar 13

Does Zai Lab’s (NASDAQ:ZLAB) Share Price Gain of 36% Match Its Business Performance?

These days it’s easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). For example, the Zai Lab Limited (NASDAQ:ZLAB) share price is up 36% in the last year, clearly besting than the market return of around 0.6% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Zai Lab hasn’t been listed for long, so it’s s...

20
MarketBeatMar 1

Stock Price, News, & Analysis for Zai Lab

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China.

1

Earnings

-$0.28
-$0.25
-$0.21
-$0.18
Q4 2016
Q1 2017
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.